…
Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally. Emergent Health Corp. was incorporated in 2006 and is based in King of Prussia, Pennsylvania. As of August 26, 2014, Emergent Health Corp was taken private.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Emergent Health Corp is an OTC Pink-listed company; public disclosures and regulatory filings are limited, so its core products, revenue sources, and operational footprint are unclear. Long-term growth would depend on establishing commercial traction, securing regulatory approvals where relevant, and accessing reliable financing or strategic partnerships, and investors may find potential upside if management delivers clearer disclosures and measurable progress.
Primary risks include extreme share illiquidity, frequent financing-related dilution, operational and regulatory uncertainty common to small OTC issuers, heightened share-price volatility, and the risk of delisting or weak corporate governance.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -1.63M | -2.11M | -0.00M | -0.00M | -0.07M |
| Net income | -1.63M | -2.11M | -0.00M | -0.00M | -0.07M |
| Selling general administrative | - | - | 0.00M | 0.00M | - |
| Selling and marketing expenses | - | - | 0.00M | 0.00M | - |
| Gross profit | 1.04M | 0.13M | 0.00M | 0.00M | 0.13M |
| Ebit | -1.41M | -1.75M | -0.00M | -0.00M | -0.06M |
| Ebitda | -1.39M | -1.73M | -0.00M | -0.00M | -0.05M |
| Depreciation and amortization | 0.02M | 0.02M | 0.00M | 0.00M | 0.01M |
| Operating income | -1.41M | -1.76M | -0.00M | -0.00M | -0.06M |
| Other operating expenses | 3.04M | 2.33M | 0.00M | 0.00M | 0.24M |
| Interest expense | 0.22M | 0.36M | - | - | 0.01M |
| Income tax expense | 0.00M | -0.00M | -0.00M | -0.00M | -0.00M |
| Total revenue | 1.64M | 0.57M | 0.00M | 0.00M | 0.18M |
| Total operating expenses | 2.45M | 1.88M | 0.00M | 0.00M | 0.19M |
| Cost of revenue | 0.60M | 0.45M | 0.00M | 0.00M | 0.05M |
| Total other income expense net | -0.22M | -0.35M | -0.00M | -0.00M | -0.01M |
| Net income applicable to common shares | - | - | -0.29M | -0.08M | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 0.53M | 0.79M | 0.00M | 0.00M | 0.40M |
| Intangible assets | 0.09M | 0.11M | 0.00M | 0.00M | - |
| Other current assets | 0.04M | 0.04M | 0.00M | 0.00M | - |
| Total liab | 2.89M | 1.85M | 0.00M | - | 0.00M |
| Total stockholder equity | -2.44M | -1.14M | -0.00M | 0.00M | 0.31M |
| Other current liab | 0.15M | 0.00M | 0.00M | - | 0.00M |
| Common stock | 0.43M | 0.26M | 0.00M | 0.00M | 0.06M |
| Retained earnings | -4.93M | -3.31M | -0.00M | -0.00M | -0.84M |
| Other assets | - | - | 0.00M | 0.00M | - |
| Cash | 0.02M | 0.01M | 0.00M | 0.00M | 0.23M |
| Total current liabilities | 2.89M | 1.85M | 0.00M | - | 0.00M |
| Net debt | 2.46M | 1.65M | -0.00M | -0.00M | -0.23M |
| Short term debt | 2.48M | 1.66M | - | - | - |
| Short long term debt total | 2.48M | 1.66M | - | - | - |
| Other stockholder equity | 2.47M | 2.14M | 0.00M | 0.00M | 1.13M |
| Total current assets | 0.40M | 0.63M | 0.00M | 0.00M | 0.31M |
| Net tangible assets | - | - | -0.13M | 0.14M | - |
| Short term investments | 0.33M | 0.33M | - | - | - |
| Net receivables | - | 0.25M | - | - | - |
| Inventory | - | - | 0.00M | 0.00M | 0.09M |
| Accounts payable | 0.25M | 0.18M | 0.00M | - | - |
| Accumulated other comprehensive income | -0.43M | -0.26M | 0.00M | 0.00M | -0.06M |
| Non currrent assets other | 0.00M | 0.00M | -0.00M | -0.00M | 0.09M |
| Non current assets total | 0.14M | 0.16M | 0.00M | 0.00M | 0.09M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Change to liabilities | - | - | 0.01M | -0.00M | - |
| Total cashflows from investing activities | 0.16M | -0.63M | - | - | - |
| Net borrowings | - | - | 0.25M | 0.25M | - |
| Total cash from financing activities | 1.07M | 2.30M | 0.00M | 0.25M | 0.09M |
| Net income | -1.63M | -2.11M | -0.00M | -0.00M | -0.07M |
| Change in cash | 0.01M | -0.24M | 0.00M | -0.00M | -0.59M |
| Begin period cash flow | 0.01M | 0.26M | 0.00M | 0.00M | 0.81M |
| End period cash flow | 0.02M | 0.01M | 0.00M | 0.00M | 0.23M |
| Total cash from operating activities | -1.22M | -1.90M | -0.00M | -0.00M | -0.05M |
| Depreciation | 0.02M | 0.02M | 0.00M | 0.00M | 0.01M |
| Other cashflows from investing activities | 0.16M | -0.58M | - | - | - |
| Change to inventory | - | 0.07M | 0.00M | 0.00M | 0.00M |
| Other cashflows from financing activities | 0.16M | -0.63M | 0.00M | - | - |
| Change to netincome | - | - | -0.00M | 0.00M | - |
| Capital expenditures | 0.00M | 0.05M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.07M | 0.19M | 0.00M | 0.00M | 0.00M |
| Other non cash items | 0.32M | -0.21M | 0.00M | -0.00M | -0.00M |
| Free cash flow | -1.22M | -1.95M | -0.00M | -0.00M | -0.05M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| EMGE Emergent Health Corp |
- -% |
0.00 | - | - | 0.36 | - |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 |
Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally. Emergent Health Corp. was incorporated in 2006 and is based in King of Prussia, Pennsylvania. As of August 26, 2014, Emergent Health Corp was taken private.
10120 Valley Forge Circle, King of Prussia, PA, United States, 19406
484-518-9000
| Name | Title | Year Born |
|---|---|---|
| Mr. James W. Zimbler | Chief Exec. Officer | 1966 |
| Mr. Gregory McCauley | Corp. Counsel | NA |
| Mr. Marvin Segel | Director & CMO | NA |
| Mr. James W. Zimbler | Chief Executive Officer | 1961 |
| Mr. Gregory McCauley | Corporate Counsel | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.